ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Long Noncoding RNA H19X Is a Master Regulator of Extracellular Matrix Production in Systemic Sclerosis and Other Fibrotic Disease

Elena Pachera1, Shervin Assassi2, Gloria Salazar2, Mojca Frank Bertoncelj1, Rucsandra Dobrota1, Matthias Brock3, Fina Kurreeman4, Jeska K. de Vries-Bouwstra4, Tobias Messemaker4, Carol Feghali-Bostwick5, Jeorg HW Distler6, Gabriela Kania1 and Oliver Distler1, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 3Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 6Internal Medicine 3, University of Erlangen, Erlangen, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Collagen, extracellular matrix proteins, fibrosis and systemic sclerosis, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Long noncoding RNAs (lncRNAs) are an emerging class of large noncoding transcripts involved in the regulation of gene expression in health and disease. We have recently identified a novel lncRNA, H19X, which is strictly regulated by TGFβ in a dose and time dependent manner. Here we aim to characterize the expression of H19X in Systemic Sclerosis (SSc) and other fibrotic diseases as well as its function in fibrotic events.

Methods:  Skin and lung biopsies from patients with SSc, idiopathic pulmonary fibrosis (IPF), and healthy controls (HC) were obtained from cohorts at four different expert centers. Expression of H19X was analyzed by RNA Sequencing Ilumina HiSeq2000 and quantitative (q)PCR respectively. The function of H19X was investigated in skin fibroblasts transfected with locked nucleic acid oligonucleotides (LNA GapmeRs) by using the following methods: microarray analysis, qPCR, immunofluorescence, sircol, contraction assay, ELISA and Western blot (WB). In situ hybridization of H19X in SSc dermal fibroblast was performed using Stellaris FISH probes.

Results:  H19X expression was consistently upregulated across all the four cohorts (SSc n=34, HC= 26), using different techniques. The upregulation was also consistent across different subsets of patients and between patients with different disease durations. H19X showed a similar expression profile in clinically non-fibrotic and clinically fibrotic skin biopsies indicating a role in early disease development. Moreover, H19X expression was also significantly increased in SSc interstitial lung disease patients versus HC (n=11 each, p<0.05). A significant H19X overexpression was also detected in IPF samples suggesting a broader role of H19X in fibrotic diseases (n=11 each, p<0.05). Microarray analysis after H19X silencing revealed a strong involvement in extracellular matrix production with collagens being the most downregulated genes. Accordingly, collagen catabolic process, extracellular matrix organization and extracellular matrix disassembly were among the pathways with highest number of enriched genes. Downregulation of collagen Iα1, fibronectin and α-smooth muscle actin (αSMA) after H19X knockdown was confirmed by qPCR (n=5, p<0.05). Sircol assay for pan-collagen production, ELISA for pro-collagen Iα1 and WB analysis for fibronectin confirmed the importance of H19X in the regulation of extracellular matrix components. Additionally, silencing of H19X significantly impaired αSMA fiber formation, stress fiber formation as well as cell contractility strongly suggesting an important role of H19X in the development of the myofibroblast phenotype (n=5-6, p<0.05). Cell fractionation showed that TGFβ induced expression of H19X is localized mainly into the nucleus. In situ hybridization confirmed H19X localization as mainly nuclear and within a defined spot indicating that H19X could influence gene expression by interacting directly with the chromatin (n=4).

Conclusion:  This is the first study reporting a significant upregulation of H19X expression in SSc and across fibrotic organs. By focusing on this novel class of regulatory, noncoding RNAs new perspectives in the pathogenesis of fibrotic diseases are opened.


Disclosure: E. Pachera, None; S. Assassi, Boehringer Ingelheim, 5,Genentech and Biogen IDEC Inc., 2,Bayer HealthCare, 2; G. Salazar, None; M. Frank Bertoncelj, None; R. Dobrota, None; M. Brock, None; F. Kurreeman, None; J. K. de Vries-Bouwstra, None; T. Messemaker, None; C. Feghali-Bostwick, None; J. H. Distler, None; G. Kania, Bayer, 2; O. Distler, Bayer, Sanofi, Ergonex, Boehringer Ingelheim, Actelion, Pfizer, 2,4 D Science, Actelion, Active Biotec, Bayer, BiogenIdec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare foundation, Genentech/Roche, GSK, Inventiva, Lilly, medac, MedImmune, Pharmacyclics, Pfizer, Serodapharm, Sinoxa, 5.

To cite this abstract in AMA style:

Pachera E, Assassi S, Salazar G, Frank Bertoncelj M, Dobrota R, Brock M, Kurreeman F, de Vries-Bouwstra JK, Messemaker T, Feghali-Bostwick C, Distler JH, Kania G, Distler O. Long Noncoding RNA H19X Is a Master Regulator of Extracellular Matrix Production in Systemic Sclerosis and Other Fibrotic Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/long-noncoding-rna-h19x-is-a-master-regulator-of-extracellular-matrix-production-in-systemic-sclerosis-and-other-fibrotic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-noncoding-rna-h19x-is-a-master-regulator-of-extracellular-matrix-production-in-systemic-sclerosis-and-other-fibrotic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology